Experience

Davis Polk advised the managers for a Hong Kong law Regulation S only offering by AVIC International Finance & Investment Limited of its $400 million 4.375% guaranteed bonds due…

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant Pharmaceuticals…

Davis Polk advised the underwriters in connection with the SEC-registered Schedule B debt offerings by KEXIM of $800 million aggregate principal amount of its floating-rate notes due…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Valero Energy Corporation of $750 million aggregate principal amount of its 4.350% senior notes due…

Davis Polk advised The Metropolis of Tokyo in connection with its $500 million Rule 144A/Regulation S offering of 3.250% bonds due 2023. The Davis Polk corporate team included partner Jon…

Davis Polk advised the lead bookrunning managers and joint global coordinators in connection with a Rule 144A/Regulation S offering by Yara International ASA of $1 billion principal…

Davis Polk advised Israel Chemicals Limited in connection with its 144A/Regulation S notes offering of $600 million aggregate principal amount of 6.375% senior notes due 2038.  Davis…

Davis Polk is advising GAIN Capital Holdings, Inc. on the $100 million sale of its GTX ECN business, an institutional platform for trading foreign exchange, to Deutsche Börse Group via its…

Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial public offering of 6,150,000 ordinary shares, at $13.00 per…

Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 24,640,000 shares of common stock of Melinta Therapeutics, Inc., including…